CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform) : A multicenter preclinical network for testing reproducibility in cardiovascular interventions
Rossello, Xavier (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Rodriguez-Sinovas, Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau)
Crisóstomo, Verónica (Centro de Cirugía de Mínima Invasión Jesús Usón)
Jorge, Inmaculada (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Zaragoza, Carlos (Universidad Francisco de Vitoria)
Zamorano, José Luis (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid))
Bermejo, Javier (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Ordoñez, A. (Instituto de Biomedicina de Sevilla)
Boscá, Lisardo (Instituto de Investigaciones Biomédicas Alberto Sols (Centro Mixto CSIC-UAM))
Vázquez, Jesús (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Sánchez-Margallo, F. M. (Centro de Cirugía de Mínima Invasión Jesús Usón)
Fernández Avilés, F. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
García-Dorado, David (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ibanez, Borja (Hospital Universitario Fundación Jiménez Díaz)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the "Cardioprotection Large Animal Platform" (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.
Note:	Altres ajuts: Groups part of the CIBERCV receive competitive structural funding from the Insituto de Salud Carlos III (ISCiii) through the Ministry of Science, Innovation and Universities (MICINN). X.R. has received support from the SEC-CNIC CARDIOJOVEN fellowship program.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Scientific reports, Vol. 9 Núm. 1 (january 2019) , p. 20290, ISSN 2045-2322

DOI: 10.1038/s41598-019-56613-6
PMID: 31889088

11 p, 1.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles